SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies
Viruses · 28.04.2024 · 16 (5) · 697
DOI: 10.3390/v16050697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 28.04.2024. Verfasst von Hailong Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: IGM Biosciences, Mountain View, CA 94043, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Immune Evasion, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Welch Foundation.
Abstract (Originalsprache)
Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns has revoked all authorized immunotherapeutics. Rapid viral evolution has also necessitated several rounds of vaccine updates in order to provide adequate immune protection. It remains imperative to understand how Omicron evolves into different subvariants and causes immune escape as this could help reevaluate the current intervention strategies mostly implemented in the clinics as emergency measures to counter the pandemic and, importantly, develop new solutions. Here, we provide a review focusing on the major events of Omicron viral evolution, including the features of spike mutation that lead to immune evasion against monoclonal antibody (mAb) therapy and vaccination, and suggest alternative durable options such as the ACE2-based experimental therapies superior to mAbs to address this unprecedented evolution of Omicron virus. In addition, this type of unique ACE2-based virus-trapping molecules can counter all zoonotic SARS coronaviruses, either from unknown animal hosts or from established wild-life reservoirs of SARS-CoV-2, and even seasonal alpha coronavirus NL63 that depends on human ACE2 for infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IGM Biosciences, Mountain View, CA 94043, USA.
- Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT 05405, USA.
- Department of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT 05405, USA.
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
ORCID-Profile: Hailong Guo, Kai Xu, Tong-Ming Fu
Förderung
- NIAID NIH HHS
- Welch Foundation
Zitieren
APA
Guo, H., Ha, S., Botten, J. W., Xu, K., Zhang, N., An, Z., Strohl, W. R., Shiver, J. W., & Fu, T. M. (2024). SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies. Viruses, 16(5), 697. https://doi.org/10.3390/v16050697
Vancouver
Guo H, Ha S, Botten JW, Xu K, Zhang N, An Z, et al. SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies. Viruses. 2024;16(5):697. doi:10.3390/v16050697
BibTeX
@article{Guo2024,
author = {Guo, Hailong and Ha, Sha and Botten, Jason W and Xu, Kai and Zhang, Ningyan and An, Zhiqiang and Strohl, William R and Shiver, John W and Fu, Tong-Ming},
title = {SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies},
journal = {Viruses},
year = {2024},
volume = {16},
number = {5},
pages = {697},
doi = {10.3390/v16050697}
}
EUVIMED